Can AI Drug Discovery Expand Algorae’s Valuation? The Answer Is Not in the Algorithm Itself

In capital markets, AI drug discovery is often packaged as a shortcut for shortening R&D timelines and reducing the cost of failure. But for a small listed pharmaceutical company, if that story is to become measurable corporate value, it must move from an attractive concept to more basic questions: what molecules it has identified, what data it used to make those judgments, what experiments have validated them, and whether the next step is strong enough to support clinical development or partnership negotiations.

On June 23, Kalkine discussed whether AI drug discovery could unlock more value for Algorae Pharmaceuticals (ASX: 1AI). The report approached the topic from an investment perspective, but the public summary did not provide details such as specific drug candidates, disease areas, model design, dataset scale, or experimental results. For now, it is therefore more appropriate to view it as another market review of the company’s AI R&D positioning, rather than a new breakthrough already fully supported by biomedical evidence.

The practical use of AI in drug discovery is usually not as simple as having machines “invent new drugs.” More specific applications include screening compound databases for molecules that may hit a target, predicting drug-protein binding, optimizing the solubility and metabolic properties of drug-like molecules, or excluding structures that may carry toxicity and development risks at an early stage. These tasks can accelerate hypothesis generation, but they cannot replace wet-lab experiments, animal models, pharmacokinetic and pharmacodynamic assessments, or clinical trials.

For companies such as Algorae that enter investors’ field of view through an AI narrative, the key question is not only whether algorithms have been adopted, but whether those algorithms are embedded in a traceable R&D process. If a model is trained on public data of uneven quality, it may learn literature bias; if it lacks prospective validation, back-testing performance may not necessarily predict real-world experimental results. Investors and partners typically ask: Have the AI-screened candidates completed in vitro activity testing? Do they show preliminary signals of selectivity and safety? How do they differ from existing therapies or competing pipelines?

Background Context

Recently, AI biomedicine themes have gradually moved from simple model demonstrations toward stricter evidence comparisons. Fields such as antibody design, translational medicine data integration, and drug pipeline searches are all facing the same threshold: model outputs must be verifiable through experiments, literature sources, or clinical development decisions. This also means the valuation logic for AI drug-discovery companies is changing. The market no longer looks only at technical slogans, but demands clearer data governance, reproducible results, and disease strategies.

There is likewise no shortcut on the regulatory front. If AI is used only for early screening, regulators will ultimately still review the quality, safety, and efficacy of the candidate drug itself. If AI is involved in clinical trial design, patient stratification, or biomarker interpretation, model versioning, bias control, and explainability will become more direct issues. In other words, AI can change the speed and scope of the front end of R&D, but it will not allow drug development to step outside the rules of evidence.

Therefore, if Algorae’s AI drug-discovery theme is to support higher value, the next meaningful signal will not be another claim of technological potential, but more concrete milestones: a clearly defined indication, testable candidate molecules, experimental data, partnership validation, or a decision to enter preclinical development. Without these materials, AI provides room for imagination; only with reproducible biological evidence can it become a genuine R&D asset.